journal
preproof
j
u
r
n
l
p
r
e
p
r
f
tradit
drug
discoveri
focus
identifi
direct
inhibitor
target
protein
approach
typic
reli
specif
measur
biochem
readout
amen
bind
site
occup
directli
influenc
target
protein
function
requir
preclud
mani
diseasecaus
protein
druggabl
target
protein
categor
undrugg
proteolysistarget
chimera
protac
technolog
provid
power
tool
degrad
undrugg
target
becom
promis
approach
drug
discoveri
howev
protac
technolog
may
limit
emerg
new
degrad
technolog
may
greatli
broaden
spectrum
target
could
select
degrad
har
anoth
major
degrad
pathway
cell
review
key
emerg
technolog
exploit
lysosom
degrad
pathway
discuss
potenti
applic
well
limit
journal
preproof
j
u
r
n
l
p
r
e
p
r
f
j
u
r
n
l
p
r
e
p
r
f
cullinf
box
complex
lead
ubiquitin
degrad
dosedepend
manner
howev
covalentlybound
moieti
peptid
hinder
applic
toward
therapeut
research
due
larg
molecul
size
lead
poor
cellular
penetr
cellperm
protac
molecul
link
nonsteroid
androgen
receptor
ligand
sarm
ligand
nutlin
pegbas
linker
synthes
protac
molecul
induc
ubiquitin
androgen
receptor
subsequ
degrad
proteasom
protac
system
base
major
ligas
ubiquitin
tumor
suppressor
protein
nutlin
famili
consist
small
molecul
bind
pocket
thu
competit
inhibit
interact
induc
possibl
offtarget
effect
nutlin
improv
superior
potenc
select
new
protac
system
use
cellular
inhibitor
apoptosi
protein
ubiquitin
ligas
establish
hashimoto
colleagu
verifi
hybrid
molecul
coupl
ligand
methyl
bestatin
ligand
crabp
induc
degrad
crabpii
cell
via
proteasom
pathway
bradner
group
first
establish
anoth
import
protac
system
base
cereblon
crbn
crbn
initi
identifi
primari
mediat
teratogen
activ
thalidomid
handa
colleagu
immunomodulatori
drug
imid
includ
thalidomid
deriv
lenalidomid
pomalidomid
later
util
treat
multipl
myeloma
imid
report
interact
crbndna
damag
bind
complex
shortli
seri
protac
molecul
consist
crbnbind
imid
connect
smallmolecul
ligand
differ
poi
design
degrad
capabl
verifi
exampl
chimer
compound
select
degrad
protein
via
crbn
anoth
protac
system
vhlprotac
system
base
deriv
peptid
initi
introduc
replac
vhltarget
peptid
hydroxyprolinelik
small
molecul
j
u
r
n
l
p
r
e
p
r
f
significantli
improv
affin
specif
vhlprotac
system
greatli
expand
applic
current
known
human
ligas
establish
protac
system
reli
less
ten
wide
use
crbn
von
hippel
lindau
vhl
ciap
discuss
one
desir
properti
protac
catalyt
involv
multipl
round
target
protein
degrad
therefor
degrad
induc
protac
substoichiometr
ie
one
protac
molecul
abl
induc
ubiquitin
degrad
multipl
poi
molecul
catalyt
natur
protac
provid
potenti
strong
degrad
power
rel
low
concentr
sometim
desir
tempor
spatial
control
power
recent
studi
develop
control
protac
photoswitch
azobenzeneprotac
azoprotac
photocag
protac
pcprotac
azoprotac
lightcontrol
smallmolecul
tool
protein
knockdown
cell
lightinduc
configur
chang
switch
activ
state
induc
protein
degrad
activ
revers
control
light
exposur
intact
cell
pcprotac
photoremov
block
group
ad
degrad
result
molecul
show
potent
degrad
activ
live
cell
light
irradi
protac
field
boom
number
potenti
limit
protac
identifi
protac
molecul
often
high
molecular
weight
da
rel
high
polar
surfac
area
like
lead
low
solubl
poor
cell
permeabl
low
oral
bioavail
well
bloodbrain
barrier
penetr
protac
effect
depend
specif
ligas
subunit
thu
influenc
express
limit
applic
certain
cell
type
depend
specif
ligas
subunit
may
also
caus
resist
cancer
cell
follow
chronic
protac
treatment
final
protac
molecul
induc
poi
degrad
via
proteasom
limit
capabl
protein
expand
repeat
sequenc
protein
aggreg
nonprotein
molecul
discuss
protac
technolog
extrem
promis
depend
express
specif
ligas
proteasom
pathway
may
limit
potenti
applic
certain
cell
type
target
certain
proteasomeresist
protein
encouragingli
novel
concept
emerg
recent
around
lysosom
degrad
pathway
major
degrad
pathway
independ
proteasom
lysosom
degrad
pathway
includ
endosomelysosom
pathway
autophagi
pathway
review
endosomelysosom
pathway
mediat
seri
transform
sever
membranebound
intracellular
compart
endocytos
materi
incorpor
proce
earli
endosom
endosom
carrier
vesicl
late
endosom
lysosom
subsequ
hydrolysi
autophagi
pathway
start
isol
membran
structur
call
phagophor
deriv
lipid
bilay
lipid
protein
phagophor
expand
engulf
intracellular
cargo
autophagi
substrat
includ
protein
biomolecul
even
organel
therebi
sequest
doublemembran
vesicl
call
autophagosom
load
autophagosom
matur
fusion
lysosom
lead
degrad
cargo
thu
endosomelysosom
pathway
autophagi
pathway
degrad
capabl
new
concept
design
demonstr
har
pathway
select
degrad
lytac
lysosom
target
chimera
technolog
promis
strategi
hijack
endosomelysosom
pathway
degrad
poi
current
publish
preprint
paper
without
peer
review
excitingli
lytac
molecul
may
work
extracellular
protein
well
membranebound
protein
egfr
type
protein
typic
resist
protac
mainli
target
intracellular
protein
lytac
molecul
consist
antibodi
specif
poi
coval
attach
antibodi
glycan
mark
target
protein
degrad
bind
j
u
r
n
l
p
r
e
p
r
f
cationindepend
receptor
thu
antibodi
ie
lytac
molecul
recogn
endogen
system
lysosom
degrad
glycosyl
protein
bring
poi
togeth
lysosom
degrad
certain
case
antibodi
could
replac
polypeptid
ligand
conjug
small
molecul
bind
poi
author
confirm
polypeptid
multipl
ligand
attach
biotin
high
affin
binder
avidin
target
extracellular
neutravidin
protein
endosom
lysosom
advantag
lytac
technolog
enabl
degrad
extracellular
membran
poi
util
ubiquit
express
endogen
degrad
pathway
major
limit
lytac
molecul
quit
larg
thu
lose
desir
properti
smallmolecul
compound
drug
antibodi
polypeptid
natur
molecul
may
also
induc
immun
respons
lytac
technolog
target
extracellular
andor
membran
poi
endosomelysosom
pathway
inapplic
cytosol
protein
could
target
autophagi
thu
autophagytarget
degrad
technolog
highli
desir
cytosol
poi
especi
resist
protac
molecul
sever
differ
type
autophagi
typic
refer
macroautophagi
multistep
cellular
process
cargo
protein
engulf
autophagosom
form
intracellular
doublemembran
contain
lipid
protein
meanwhil
autophagi
receptor
may
recogn
polyubiquitin
protein
cargo
shuttl
autophagosom
subsequ
clearanc
process
refer
select
autophagi
two
independ
new
degrad
technolog
har
autophagi
pathway
report
recent
autophagytarget
chimera
autac
system
util
similar
design
protac
technolog
autac
protac
molecul
function
via
ubiquitin
howev
instead
tether
poi
ligas
subunit
trigger
u
r
n
l
p
r
e
p
r
f
ubiquitin
autac
molecul
trigger
recogn
select
autophagi
pathway
degrad
target
poi
autac
molecul
contain
degrad
tag
guanin
deriv
ligand
poi
provid
target
specif
degrad
tag
mimic
sguanyl
posttransl
modif
cyscgmp
adduct
form
treatment
similar
compound
author
suggest
sguanyl
standalon
tag
destin
substrat
protein
select
autophagi
induc
author
show
encourag
result
autac
molecul
capabl
degrad
poi
well
cellular
organel
damag
mitochondria
design
autac
cleverli
util
process
defend
cell
invad
group
streptococcu
meanwhil
autac
molecul
function
complic
multiplestep
process
need
clarifi
particular
molecular
mechan
mediat
sguanyl
trigger
poi
need
resolv
effici
potenti
offtarget
effect
pathway
need
determin
inform
requir
clarifi
protein
requir
autac
system
autac
system
may
influenc
mediat
whether
hijack
pathway
may
caus
chang
cellular
function
addit
whether
autac
molecul
may
influenc
select
autophagi
process
per
se
whether
function
vivo
need
investig
concept
autophagosometeth
compound
attec
illustr
direct
strategi
har
autophagi
degrad
poi
differ
protac
autac
attec
molecul
independ
ubiquitin
instead
attec
molecul
tether
poi
autophagosom
direct
bind
poi
key
autophagosom
protein
proofofconcept
studi
establish
highthroughput
screen
strategi
identifi
compound
target
mutant
htt
protein
mhtt
huntington
diseas
hd
caus
protein
expand
polyglutamin
polyq
stretch
studi
j
u
r
n
l
p
r
e
p
r
f
demonstr
compound
degrad
mhtt
cell
vivo
anim
model
rescu
hdrelev
phenotyp
studi
also
confirm
compound
target
mhtt
autophagsom
subsequ
degrad
without
influenc
autophagi
activ
per
se
counterscreen
binder
wildtyp
htt
protein
wthtt
discov
attec
molecul
alleleselect
ie
degrad
mhtt
without
influenc
wthtt
level
vitro
experi
reveal
compound
specif
interact
expand
polyq
stretch
possibl
recogn
uniqu
structur
featur
differ
short
polyq
stretch
thu
discov
attec
molecul
also
capabl
degrad
diseasecaus
polyq
protein
mutant
caus
spinocerebellar
ataxia
type
iii
discov
attec
molecul
abl
pass
bloodbrain
barrier
function
nm
concentr
provid
encourag
entri
point
drug
discoveri
interact
autophagosom
protein
directli
bypass
ubiquitin
process
attec
molecul
may
great
potenti
degrad
differ
type
cargo
includ
autophagyrecogn
nonprotein
cargo
dnarna
molecul
damag
organel
etc
via
direct
mechan
attec
molecul
influenc
global
autophagi
activ
wherea
remain
elucid
autac
import
perturb
global
autophagi
may
minim
nonspecif
degrad
function
protein
organel
studi
desir
develop
attec
compound
compart
interact
remain
resolv
attec
molecul
unlik
protac
lytac
autac
discov
attec
molecul
target
mhtt
small
size
compar
rel
larg
chimer
compound
linker
two
separ
chemic
moieti
interact
poi
degrad
machineri
respect
whether
could
develop
function
chimer
molecul
attach
warhead
poi
bind
compound
remain
test
hand
small
compound
may
advantag
better
drug
properti
emerg
new
concept
degrad
technolog
especi
novel
one
around
autophagiclysosom
degrad
pathway
may
greatli
expand
landscap
applic
degrad
technolog
current
studi
mainli
focus
pathogen
protein
new
concept
could
also
explor
capabl
degrad
pathogen
target
solubl
protein
protein
aggreg
dnarna
molecul
peroxisom
ribosom
damag
mitochondria
even
microbi
pathogen
briefli
discuss
futur
possibl
use
concept
degrad
target
potenti
exampl
futur
applic
technolog
mani
neurodegen
diseas
includ
alzheim
diseas
parkinson
diseas
huntington
diseas
associ
format
protein
aggregatesoligom
misfold
protein
clear
protein
aggregatesoligom
without
affect
wildtyp
counterpart
like
promis
drug
discoveri
paradigm
given
poor
capabl
proteasom
degrad
aggregatesoligom
autophagi
hijack
degrad
may
better
capabl
target
protein
aggreg
select
degrad
least
theori
consist
one
discov
attec
molecul
reduc
mutant
htt
aggreg
significantli
given
relev
diseas
neurolog
molecul
high
lipid
solubl
molecular
weight
da
desir
expect
higher
chanc
cross
bloodbrain
barrier
via
passiv
diffus
thu
degrad
smaller
molecular
weight
may
better
chanc
develop
drug
candid
treatment
neurodegener
interestingli
tau
degrad
j
u
r
n
l
p
r
e
p
r
f
recent
report
base
protac
system
compound
effici
degrad
neurodegenerationrel
solubl
tau
protein
tau
aggregatestangl
test
tau
speci
might
degrad
effici
emerg
lysosomebas
technolog
neurodegen
disord
may
also
lead
alter
lysosomerel
function
take
huntington
diseas
exampl
mainstream
evid
show
increas
presenc
endocyt
autophag
compart
reduc
cargomhtt
recognit
justifi
enhanc
recognit
pathogen
protein
degrad
technolog
attec
meanwhil
certain
diseas
sever
lysosom
deficit
correct
lysosom
function
per
se
probabl
import
rna
molecul
could
directli
recogn
lysosom
membran
protein
load
lysosom
degrad
studi
reveal
put
rna
transport
mediat
rna
transloc
across
lysosom
membran
thu
scientist
may
screen
highaffin
bind
molecul
attach
antisens
oligonucleotid
small
molecul
specif
bind
target
rna
chimer
molecul
may
select
degrad
target
rna
knock
encod
pathogen
protein
may
provid
novel
degrad
technolog
rna
addit
recent
nucleasetarget
rna
degrad
technolog
develop
disney
group
dna
molecul
clearanc
cytosol
dna
molecul
patholog
condit
highli
desir
cyclic
gmpamp
cgamp
synthas
cga
detect
infect
tissu
damag
bind
microbi
self
dna
cytoplasm
upon
bind
dna
cga
produc
cgamp
bind
activ
adaptor
protein
sting
induc
lipid
activ
autophagi
cgampinduc
autophagi
critic
clearanc
dna
virus
cytosol
provid
promis
possibl
use
autophagytarget
degrad
technolog
enhanc
clearanc
dna
molecul
relev
pathogen
damag
cellular
compon
sinc
cytosol
dna
could
ubiquitin
suitabl
degrad
technolog
j
u
r
n
l
p
r
e
p
r
f
probabl
attec
scientist
may
use
attec
concept
design
molecul
consist
target
dna
bind
molecul
attach
chemic
moieti
chimer
attec
molecul
may
tether
dna
subsequ
autophag
degrad
bacteri
viral
infect
present
sever
global
threat
healthcar
antibiot
treatment
obtain
enorm
success
new
therapeut
approach
desir
due
rise
antibioticresist
infect
dearth
new
antibiot
pipelin
select
autophagi
major
intracellular
pathway
target
intracellular
pathogen
lysosom
degrad
process
refer
xenophagi
thu
autophagylysosom
degrad
technolog
attec
autac
could
use
target
key
protein
pathogen
lead
enhanc
clearanc
via
xenophagi
approach
may
provid
synergist
effect
xenophagi
enhanc
approach
studi
recent
control
bacteri
infect
anoth
potenti
strategi
target
microbi
dnarna
autophag
degrad
attec
discuss
previou
paragraph
pathogen
respons
recent
pneumonia
outbreak
could
target
design
well
see
outstand
question
meanwhil
mani
pathogen
evolv
way
subvert
exploit
defens
mechan
minim
actual
effect
xenophagi
innat
immun
better
understand
complic
relationship
autophagi
microbi
pathogen
provid
better
opportun
combin
novel
degrad
technolog
xenophagi
enhanc
approach
achiev
optim
therapeut
effect
emerg
new
concept
degrad
technolog
design
har
rel
nonspecif
lysosom
degrad
pathway
select
degrad
poi
concept
greatli
expand
landscap
therapeut
target
provid
excit
novel
approach
potenti
therapeut
benefit
lytac
util
glycan
tag
mark
extracellular
poi
intracellular
lysosom
degrad
follow
receptor
mediat
intern
autac
cleverli
exploit
smallmolecul
mimic
sguanyl
select
tag
poi
ubiquitin
induc
lysosom
degrad
via
select
autophagi
hand
attec
exploit
lipid
directli
tether
polyq
protein
grow
autophagosom
facilit
select
remov
via
autophagi
meanwhil
critic
concern
address
matur
establish
technolog
specif
potenti
offtarget
effect
need
clarifi
technolog
see
outstand
question
proteom
studi
perform
attec
cellular
tissu
sampl
studi
lytac
autac
current
miss
besid
proteom
studi
measur
steadyst
protein
level
research
may
consid
investig
whether
compound
interact
protein
design
target
scientist
may
pulldown
compoundbind
protein
cell
tissu
lysat
perform
proteom
analysi
pulldown
sampl
reveal
potenti
offtarget
bind
partner
addit
whether
technolog
catalyt
may
function
substoichiometr
need
clarifi
see
outstand
question
theori
autac
attec
could
catalyt
small
molecul
autac
attec
could
recycl
lysosom
degrad
target
protein
need
test
valid
lytac
molecul
like
noncatalyt
current
larg
biomolecular
natur
noncatalyt
natur
compound
function
may
lead
less
effici
yet
control
degrad
compar
catalyt
technolog
also
specif
concern
address
emerg
technolog
see
outstand
question
larg
lytac
molecul
desir
reduc
small
molecul
easier
deliveri
prevent
immun
respons
achiev
scientist
may
identifi
small
molecul
bind
screen
structurebas
design
address
interactom
studi
protein
recogn
modif
biochem
screen
modifi
sguanylationinduc
potenti
influenc
autophagi
autac
also
need
test
compar
lytac
autac
studi
biolog
effect
attec
molecul
investig
rel
thoroughli
meanwhil
atom
level
structur
inform
compoundprotein
interfac
critic
attec
remain
solv
chimer
attec
molecul
also
need
design
b
schemat
illustr
autac
autac
bind
poi
add
degrad
tag
mimick
sguanyl
posttransl
modif
trigger
poi
poi
recogn
autophagi
receptor
protein
recruit
select
autophagi
pathway
degrad
autac
molecul
g
pentagon
repres
chemic
moieti
mimick
sguanyl
link
pacman
shape
repres
target
recogn
part
c
schemat
illustr
attec
attec
interact
poi
tether
poi
phagophor
autophagosom
directli
subsequ
autophag
degrad
